We are live on ! Find out more
ICCM icon

IceCure Medical

12 hedge funds and large institutions have $169K invested in IceCure Medical in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.11% less ownership

Funds ownership: 0.39% → 0.28% (-0.11%)

19% less capital inflows, than outflows

Capital inflows: $57.5K | Capital outflows: $71.4K

20% less funds holding

Funds holding: 15 → 12 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
12
Holders Change
-3
Holders Change %
-20%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ICCM Hedge Fund Activity: Q4 2024 in Review

12 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in IceCure Medical (ICCM) for Q4 2024, worth a combined $169K — up 43% from $118K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ICCM and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was XTX Topco, adding an estimated $24.8K. The largest seller was UBS Group, exiting entirely with an estimated $36.5K sold.

  • 12 institutional investors held IceCure Medical (ICCM) as of Q4 2024, down from 15 in Q3 2024.
  • Funds reported $169K of IceCure Medical stock for Q4 2024, up 43% quarter-over-quarter.
  • 2 funds opened new IceCure Medical positions in Q4 2024 and 5 closed out, a net change of -3 holders.
  • The largest IceCure Medical buyer in Q4 2024 was XTX Topco, an estimated $24.8K added.
  • The largest IceCure Medical seller in Q4 2024 was UBS Group, an estimated $36.5K sold.

Based on aggregated 13F filings for Q4 2024.